Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines
- 30 June 2012
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 39 (3), 296-304
- https://doi.org/10.1053/j.seminoncol.2012.02.010
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute
This publication has 59 references indexed in Scilit:
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Improved Endpoints for Cancer Immunotherapy TrialsJNCI Journal of the National Cancer Institute, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009
- Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populationsCancer Immunology, Immunotherapy, 2009
- Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cellsCancer Immunology, Immunotherapy, 2008
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyThe Journal of Experimental Medicine, 2006
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisThe New England Journal of Medicine, 2000